Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma

Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published docum...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Xavier Armoiry, Hans-Martin Spath, Aileen Clarke, Martin Connock, Paul Sutcliffe, Claude Dussart
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis Group 2019-01-01
Reeks:Journal of Market Access & Health Policy
Onderwerpen:
nice
has
health technology assessment
france
england
ixazomib
multiple myeloma
Online toegang:http://dx.doi.org/10.1080/20016689.2019.1648971
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items